AbbVie announces updated phase 3 RESOLVE trial of ibrutinib in metastatic pancreatic cancer

AbbVie, a research─based global biopharmaceutical company, announced an update on the phase 3 RESOLVE trial (PCYC─1137) of ibrutinib (Imbruvica) in combination with chemotherapy agents nab─paclitaxel and

More From BioPortfolio on "AbbVie announces updated phase 3 RESOLVE trial of ibrutinib in metastatic pancreatic cancer"